Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis of real-world data (RWD). RWD and RWE are playing an increasing role in health care decisions. They can be used to support regulatory decision-making, clinical trial designs, guideline development, and healthcare policy-making.
Understanding the intent of the use of RWE in the design and conduct of an RWE study is critical for several reasons:
[1] Regulatory Requirements: The regulatory standards for evidence used to support different types of decisions can vary substantially. For instance, the data standards required by the FDA for a new drug approval (which often rely on randomized clinical trials) are much more stringent than the standards for post-marketing surveillance or comparative effectiveness research. Understanding the end use of the evidence helps in designing a study that meets the appropriate regulatory standards and complies with the relevant requirements.
[2] Data Integrity and Quality: The quality of RWD can vary widely, depending on the source. If the evidence is being used to support high-stakes decisions (like regulatory approval), the data used must be of very high integrity and quality. For instance, data from electronic health records or insurance claims may be sufficient for some types of observational studies, but they might not be adequate for regulatory decisions without additional validation.
[3] Study Design: The intent of the study impacts the choice of study design. For instance, randomized controlled trials are considered the gold standard for demonstrating cause-effect relationships and are often required for regulatory approval. However, if the goal is to understand how a treatment works in routine clinical practice, an observational study using RWD might be more appropriate.
[4] Data Analysis: The intent of the RWE study also determines the methods used to analyze the data. For example, methods to control for confounding factors, which can bias the results, might be more critical in studies used for regulatory decision-making than in those used for exploratory analyses.
[5] Ethical Considerations: Depending on the intent, different ethical considerations might apply. For instance, if the RWE study is designed to inform clinical decision-making, it’s crucial to ensure that patient privacy is protected, informed consent is obtained (when required), and results are communicated transparently.
In summary, understanding the intended use of RWE is crucial in the design and conduct of an RWE study because it impacts everything from the regulatory requirements to the quality and integrity of data used, to the choice of study design and data analysis methods, to the ethical considerations. These considerations can substantially influence the validity, generalizability, and acceptability of the study’s results.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







